Compare ACCO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | SABS |
|---|---|---|
| Founded | 1893 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 344.8M |
| IPO Year | 2005 | 2020 |
| Metric | ACCO | SABS |
|---|---|---|
| Price | $4.38 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $8.00 | ★ $11.64 |
| AVG Volume (30 Days) | 535.4K | ★ 561.0K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 6.91% | N/A |
| EPS Growth | ★ 141.51 | 78.53 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.81 | $2.10 |
| 52 Week High | $4.56 | $5.15 |
| Indicator | ACCO | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 29.92 |
| Support Level | $4.15 | N/A |
| Resistance Level | $4.56 | $4.07 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 100.00 | 28.17 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.